ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
5.71
-0.43 (-7.00%)
Mar 31, 2025, 1:15 PM EDT - Market open

Company Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States.

Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.

The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers.

It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor.

The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals logo
Country United States
Founded 2014
IPO Date Apr 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 115
CEO Jacob Chacko

Contact Details

Address:
240 East Grand Avenue, 2nd Floor
South San Francisco, California 94080
United States
Phone 650 388 5600
Website oricpharma.com

Stock Details

Ticker Symbol ORIC
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001796280
CUSIP Number 68622P109
ISIN Number US68622P1093
Employer ID 47-1787157
SIC Code 2834

Key Executives

Name Position
Dr. Jacob M. Chacko M.B.A., M.D. President, Chief Executive Officer and Director
Dr. Richard A. Heyman Ph.D. Co-Founder, Independent Chairman and Member of Scientific Advisory Board
Dominic G. Piscitelli CPA, M.B.A. Chief Financial Officer
Dr. Pratik S. Multani M.D., M.S. Chief Medical Officer
Dr. Charles L. Sawyers B.A., M.D., Ph.D. Co-Founder and Member of Scientific Advisory Board
Dr. Scott W. Lowe Ph.D. Co-Founder and Member of Scientific Advisory Board
Dr. Lori Sickels Friedman Ph.D. Chief Scientific Officer
Dr. Christian V. Kuhlen Esq., J.D., M.D. General Counsel
Daniel Iazzetti Vice President and Head of People
Dr. Edna Chow Maneval Ph.D. Executive Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Mar 20, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 14, 2025 8-K Current Report
Feb 25, 2025 8-K Current Report
Feb 18, 2025 10-K Annual Report
Feb 18, 2025 8-K Current Report
Feb 12, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Dec 16, 2024 144 Filing
Dec 16, 2024 144 Filing
Dec 16, 2024 144 Filing